The risk ratio of hypoglycemia for SGLT-2 inhibitors plus sulfonylureas versus placebo plus sulfonylureas was 1.67 (1.42 to 1.97), with no evidence of heterogeneity across the trials (P=0.78, I2 = 0%; Figure 3). Here, SLC5A2 is linked to Hypoglycemia.